Literature DB >> 10509894

A new Lp(a) assay that is unaffected by apo(a) size polymorphism.

S Yamada1, K Inoue, R Morishita, T Ogihara, K Kubono, N Kubo, A Abe, I Sakurabayashi.   

Abstract

We developed sandwich ELISA methods in which anti-apo(a) kringle 4 type 5 through protease (K4 x 5-Pro) domain monoclonal antibody (clone: 203E2) is employed in each instance as the capture antibody and one of the three species of monoclonal antibody [Mab] (clones: 108B8, 202A9, 2B3) is used as the labeled antibody. Using serum containing apo(a) with 34 repeats of kringle 4 as the calibrator, a commercial kit using anti-Lp(a) polyclonal antibody (Pab) or anti-apo(a) Mab overestimated the Lp(a) concentration in samples containing apo(a) with more than 34 repeats of kringle 4 and underestimated the Lp(a) concentration in samples containing apo(a) with fewer than 34 repeats of kringle 4. Moreover, it was demonstrated that the ratios of commercial kit values to anti-apo(a) K4 x 5-Pro Mab-based method values increased as the size of apo(a) increased. The ratios of apo(a) K5 x Pro Mab-based method values to anti-apo(a) K4 x 5-Pro Mab-based method values, however, remained almost constant regardless of the size polymorphism. Thus, we suggest that apo(a) size heterogeneity can significantly affect Lp(a) measurement in the Lp(a) assay using anti-Lp(a) Pab. The novel Lp(a) assay method, using only anti-apo(a) K4 x 5-Pro Mab, is not subject to this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509894     DOI: 10.1016/s0009-8981(99)00119-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects.

Authors:  Kazuhiko Kotani; Shingo Yamada; Toshiyuki Yamada; Kazuomi Kario; Nobuyuki Taniguchi
Journal:  Heart Vessels       Date:  2012-06-19       Impact factor: 2.037

Review 2.  The role of lipoprotein[a] in atherosclerosis.

Authors:  J D Morrisett
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

3.  Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a).

Authors:  Mariko Kyutoku; Hironori Nakagami; Hiroshi Koriyama; Futoshi Nakagami; Munehisa Shimamura; Hitomi Kurinami; Hideki Tomioka; Takashi Miyake; Tomohiro Katsuya; Ryuichi Morishita
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

4.  The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein(a).

Authors:  Kazuhiko Kotani; Shingo Yamada; Toshiyuki Yamada; Nobuyuki Taniguchi; Ikunosuke Sakurabayashi
Journal:  Lipids Health Dis       Date:  2011-10-04       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.